Page 51 - Read Online
P. 51

Page 336                                Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37

             Ref.   [24]  [38]    [65]   [13]       [14]         [59]      [27]       [22]     [24]



             Clinical outcomes No association of ABCG2 No association of ABCG2   c.421C>A variant with   DGF or AR  -  No association of  SLCO1B1 *1A, *1B and *15   variants with diarrhea  SLCO1B1 c.521C allele   was associated with   reduced MPA-related   adverse events, on   cyclosporine-free   treatment  -  No association of  SLCO1B1 c.388A>G and   c.521T>C variants with   No association of  SLCO1B1 rs4149056 and  rs11045819 variants with   leukopenia  No association o








             Pharmacokinetics  c.421C>A variant with   No association of   ABCG2 c.421C>A and   rs4491984 variants with   MPA C/D (days 3-8)  No association of   SLCO1B1 *1A, *1B and   *15 variants with MPA   pharmacokinetics   -  No association of   SLCO1B1 c.388A>G,   463C>A and c.521T>C   variants with MPA or  MPAG pharmacokinetics  No association of  SLCO1B1 c.388A>G and   c.521T>C variants with  exposure to MPA, MPAG  diarrhea or leukopenia  or AcMPAG  -  -  No assoc








            Immunosuppressive   regimen  EC-MPS  Tacrolimus Corticosteroids One-year MPA C/D  follow-up  MMF  Cyclosporine  Tacrolimus  Corticosteroids   40-day follow-up  MMF  Tacrolimus  Corticosteroids   At day 28  MMF  Cyclosporine  Tacrolimus  mTOR inhibitor   Corticosteroids   One-year follow-up  MMF  Cyclosporine  Tacrolimus  Sirolimus  Corticosteroids   At a point between 3-6   months  MMF  Cyclosporine  Tacrolimus  Corticosteroids   One-year follow-up  MMF  Cyclo












             Population  97 adult patients  (Brazil)  408 adult patients   (China)  87 adult patients (Japan)  (France)  185 patients  (France)  338 adult patients   284 pediatric and young   adult patients (USA)  145 adult patients   (Brazil)  97 adult patients (Brazil)








             Study design  Prospective  Retrospective  Prospective  Retrospective (Transgene 218 adult patients   study)  Prospective (included   multicenter Apomygre   study)  Prospective  (FDCC Study)  Retrospective (Case-  Control), multicenter   Retrospective (Case-  control)  Prospective








             Allele frequency  c.421A: 10%  c.421A: 31%   rs4491984A: 50%  SLCO1B1*1A: 32%  SLCO1B1*1B: 50%  SLCO1B1*15: 18%  -11187A: 6%  c.388A: 50%   c.521C: 14%  c.388G: 44%  463A: 14%  c.521C: 18%  c.388G: 46%  c.521C: 17%  -  c.521C: 20%  c.388A: 44%   c.521C: 14%











             Variant                   rs2306283 (c.388A>G)  (c.521T>C or Val174Ala)
                                  rs4149015  (-11187G>A)   rs11045819  (463C>A)  rs4149056  rs11045819  (Pro155Thr)




             Gene                 SLCO1B1
   46   47   48   49   50   51   52   53   54   55   56